266 results about "Alkanoic acid" patented technology

Methods for obtaining a protein by culture of hybridoma cells, wherein said protein is an immunoglobulin, are disclosed. The methods involve culturing animal hybridoma cells in continuous presence of an alkanoic acid or salt thereof, which enhances protein production, wherein said alkanoic acid or salt thereof is present at 2 concentration range of 0.1 mM to 200 mM.

The invention provides methods of increasing the production of polypeptides, optionally recombinant polypeptides, from mammalian cells using xanthine derivatives or hybrid polar compounds and cultures containing the same. Combinations of inducers including a hybrid polar compound and / or a xanthine derivative and / or an alkanoic acid can also be used, optionally at temperatures less than 37° C.

The instant invention relates to a lubricant composition stabilized against the deleterious effects of heat and oxygen. The composition comprises a hydrotreated or hydrodewaxed oil and an effective antioxidant stabilizing amount of a mixture of a phenolic antioxidant; an N,N-disubstituted aminomethyl-1,2,4-triazole; an aromatic amine antioxidant; an alkyl phenoxy alkanoic acid; and an N-acyl sarcosine derivative. Optionally, further additives are added to the subject lubricant compositions.

Compounds represented by general formula I or salts thereof, wherein n is an integer of 2 or 3; R represents a straight-chain or branched saturated alkyl group having 4 or 4 carbon atoms, a cyclopentyl group, a cyclohexyl group or the like, Y represents a hydroxyl or amino group, A represents a hydrogen atom, a hydroxyl, methoxy, nitro group or the like, Q represents a hydrogen atom or a hydroxyl or methoxy group. They can be formulated to give pharmaceutical compositions that are effective as prophylactic or therapeutic agents for allergic diseases associated with IgE production inhibitors or IgE antibodies.

A formulation is described for straightening hair comprising alkanoic acids and a diluent, wherein the diluent is advantageously present at greater than 5% by volume, and more preferably greater than 20% by volume. The inventive formulation is acidic and does not use an effective amount of an alkaline hair-straightening agent to perform the hair straightening function. Instead, the step of hair straightening is accomplished by applying the non-alkaline formulation to the hair and then either leaving the formulation in the hair without rinsing or rinsing the formulation out of the hair followed by optional shampooing and / or conditioning. Consequently, a safe and surprisingly effective solution is provided for hair-straightening including hair-straightening maintenance, relaxation of curl, and reduction of frizziness (e.g., in humid weather).

Disclosed are oriented films comprising toughened poly(hydroxy-alkanoic acid) resin compositions comprising poly(hydroxyalkanoic acid) and an impact modifier comprising an ethylene copolymer made from monomers (a) ethylene; (b) one or more olefins of the formula CH2═C(R3)CO2R4, where R3 is hydrogen or an alkyl group with 1-6 carbon atoms, such as methyl, and R4 is glycidyl; and optionally (c) one or more olefins of the formula CH2═C(R1)CO2R2, where R1 is hydrogen or an alkyl group with 2-8 carbon atoms and R2 is an alkyl group with 1-8 carbon atoms, such as methyl, ethyl, or butyl. The ethylene copolymer may further be made from carbon monoxide monomers. The compositions may further comprise one or more ethylene / acrylate and / or ethylene / vinyl ester polymers, ionomers, and cationic grafting agents. Also disclosed are packaging materials and containers comprising the oriented films.

Disclosed are δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amide compounds of formula (I)and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.

A polyhydroxyalkanoate (PHA) having a desired configuration is produced using a raw material containing omega-(4-vinylphenyl)-alkanoic acid and (omega-substituted alkanoic acid in which a group having a ring structure selected from phenyl, thienyl, and cyclohexyl structures substitutes therefor on the end thereof by producing a PHA copolymer containing the corresponding 3-hydroxy-omega-(4-vinylphenyl)-alkanoate unit and the corresponding 3-hydroxy-omega-substituted alkanoate unit by making use of a microorganism capable of producing the PHA or by oxidizing a predetermined portion of the corresponding PHA.

A hair treatment composition comprises: an anionic surfactant; an amphoteric or zwitterionic surfactant; an alkyl amphoalkanoate surfactant; and an anti-dandruff agent that is in solution in the composition. The compositions have benefits in terms of perceived mildness by users and deposition of active agents, such as anti-dandruff agents.

The present invention relates to novel hypolipidemic, antihyperglycemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel beta-aryl-alpha-oxysubstituted alkylcarboxylic acids of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.

Preparation of an oil-water separation mesh membrane and its surface wettability conversion method are disclosed. The preparation of the separation mesh membrane comprises the following steps: A, a micro-nano structure is constructed on the surface of a metal mesh membrane by an oxidation method; B, the metal mesh membrane with the nicro-nano structure on the surface in the step A is put into an electric furnace to undergo thermo-oxidative treatment in the air atmosphere at the thermo-oxidative treatment temperature of 180-300 DEG C for 3-20 min; and a product is taken out of the electric furnace to obtain a superhydrophilic oleophobic mesh membrane; and C, the superhydrophilic oleophobic mesh membrane prepared in the step B is immersed in an ethanol solution of long-chain alkanoic acid or long-chain alkyl sulfhydryl at room temperature for 1-30 min, the product is taken out of the solution and then washed with ethanol, and finally the product is dried in a drying oven of 50-70 DEG C for 8-20 min so as to obtain the superhydrophobic oleophylic mesh membrane. The superhydrophobic oleophylic mesh membrane undergoes the treatment in the step B and the superhydrophilic oleophobic mesh membrane undergoes treatment in the step C so as to change surface wettability of the mesh membrane. The method is simple to operate, and the prepared mesh membrane material has good separation efficiency. In addition, surface wettability of the mesh membrane can be changed through simple operations.

Disclosed is a bearing material of a medical implant comprising a polymer such as UHMWPE and a surface active agent that is not covalently bonded to the polymer. The surface active agent includes a hydrophilic moiety or segment, such as an ethoxylated moiety, and a hydrophobic moiety or segment, such as an alkanol, alkenol, aromatic alcohol, alkylamine, alkenyl amine, alkyl aromatic alcohol, alkanoic acid, alkenoic acid, or any combination thereof. The bearing material has a reduced wear rate. Also disclosed is a method of reducing the wear rate of a polymeric bearing material of a medical implant when it articulates against a hard counterface in the presence of synovial fluid, the method comprising providing a surface active agent in the synovial fluid in close proximity to the bearing surface, the hard counterface, or both.

The invention provides methods and compositions for treating erectile dysfunction. The methods include the step of placing within the fossa navicularis of the patient an effective erection-inducing amount of a vasoactive prostaglandin composition of a semi-solid consistency. The composition comprises a vasoactive prostaglandin, a penetration enhancer, a shear-thinning polysaccharide, a lipophilic compound, and an acidic buffer system. The penetration enhancer is an alkyl-2-(N-substituted amino)-alkanoate ester, a (N-substituted amino)-alkanol alkanoate, or a mixture of these enhancers. The lipophilic compound may be an aliphatic C1 to C8 alcohol, aliphatic C2 to C30 ester, an aliphatic C8 to C30 ester, or a mixture of these. The composition includes a buffer system providing a buffered pH value for said composition in the range of about 3 to about 7.4.

The invention relates to an antifog mono or multilayer film structure comprising at least an external heat sealing layer coated with an antifog agent wherein the external heat sealing layer comprises, or is produced from, an ethylene copolymer or modified ethylene copolymer; the ethylene copolymer is a copolymer or terpolymer or tetrapolymer comprising repeat units derived from ethylene and about 5 to about 50 wt % of one or more polar monomers chosen from the group consisting of vinyl alkanoic acid, acrylic acid, alkyl acrylic acid and alkyl acrylate, the weight percentages being based on the total weight of the ethylene copolymer or modified ethylene copolymer. The mono or multilayer film structure according to the present invention is suitable, inter alia, for packaging fresh refrigerated products and enables clear view of the product inside the package.

Disclosed are oriented films comprising toughened poly(hydroxy-alkanoic acid) resin compositions comprising poly(hydroxyalkanoic acid) and an impact modifier comprising an ethylene copolymer made from monomers (a) ethylene; (b) one or more olefins of the formula CH2═C(R3)CO2R4, where R3 is hydrogen or an alkyl group with 1-6 carbon atoms, such as methyl, and R4 is glycidyl; and optionally (c) one or more olefins of the formula CH2═C(R1)CO2R2, where R1 is hydrogen or an alkyl group with 2-8 carbon atoms and R2 is an alkyl group with 1-8 carbon atoms, such as methyl, ethyl, or butyl. The ethylene copolymer may further be made from carbon monoxide monomers. The compositions may further comprise one or more ethylene / acrylate and / or ethylene / vinyl ester polymers, ionomers, and cationic grafting agents. Also disclosed are packaging materials and containers comprising the oriented films.

The present invention relates to novel chain-fluorinated alkanoic acid derivatives thereof, their synthesis, and their use as αv integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors αvβ3 and / or αvβ5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.

The invention discloses a method for deep denitrification of metaphase landfill leachate through single-stage SBR (Styrene Butadiene Rubber) post denitrification treatment, which belongs to the technical field of sewage treatment by using biochemical process. Aiming at the characteristics that the landfill leachate is high in organism concentration, high in ammonia concentration, high in C / P ratio (grater than 200), the invention discloses a real-time control method with the combination of 'anaerobic / aerobiotic / anoxic' operation modes, and SBR post denitrification is achieved. Under long-term domestication, glycan bacteria (GAO) can be enriched, volatile organic acids (VFA (Volatile Fatty Acid)) in water are converted into poly-beta-hydroxy-alkanoic acid ester (PHA) through glycogen glycolysis at an anaerobic stage by using GAO, in an aerobiotic stage (the dissolved oxygen is less than 0.8mg / L), when partial nitrification is carried out, most part of PHA is converted into glycogen, and in the anoxic stage, the residual PHA and the glycogen are utilized to perform carbon source denitrification, so that the effluent meets the latest national emission standard. The method has the advantages of simple devices, rapid starting, freedom of external carbon source, good denitrification effect, simplicity in operation, low cost and the like.

A pharmaceutical composition containing a prostaglandin and an alkanoic acid ester of a polyethoxylated sorbitol in an amount effective to enhance the chemical stability of the prostaglandin, and the use thereof for treating ophthalmic conditions. Also disclosed are methods for enhancing the chemical stability of a prostaglandin-containing composition by using an alkanoic acid ester of a polyethoxylated sorbitol.

Recombinantly produced serum albumin is purified in a series of steps, optionally by incubation with an anion-exchange adsorbent, followed by affinity chromatography employing a hydrophobic solid phase and using a water-soluble lipid anion as desorbens in the aqueous phase. The immobile phase comprises a carrier coupled to a 2-mercapto or 2-hydroxy alkanoic acid.

A method for producing a rigid, closed-cell polyurethane foam having a free-rise density of from about 1.3 lbs / ft.3 to about 4 lbs / ft.3 and exhibiting a shrinkage of less than 10%, comprises mixing together an isocyanate, at least one alkyl alkanoate blowing agent and at least one polyol having a hydroxyl number of from about 150 to about 800 and being selected from the group consisting of polyalkoxylated amines, polyalkoxylated ethers, and polyester polyols, to form a reaction mixture that is curable to produce such foam.

The present invention provides a negataively chargeable charge controlling agent to control a charged state of a powder or granular material such as toner for electrophotography, where the agent comprises a polyhydroxyalkanoate having at least one kind of 3-hydroxy-ω-carboxyalkanoic acid unit represented by the chemical formula (1): wherein n is an integer selected from 1 to 8; R1 is an H, Na or K atom, or and when more than one unit exists, n and R1 is the same or different between the units. The charge controlling agent is excellent in electrophtographic properties and propitious to environment because of the biodegradability of the polyhydroxyalkanoate. wherein n is an integer selected from the range shown in the same chemical formula; R1 is an H atom, Na atom, K atom, or and when more than one unit exists, n and R1 may differ from unit to unit.

The present invention relates to hydrogenation catalysts prepared from polyoxometalate precursors. The polyoxometalate precursors introduce a support modifier to the catalyst. The catalysts are used for hydrogenating alkanoic acids and / or esters thereof to alcohols, preferably with conversion of the ester coproduct. The catalyst may also comprise one or more active metals.

Disclosed are blended latex dispersions which can be used as binders in paper coating compositions. Such latex dispersions comprise a first copolymer of a vinyl ester of an alkanoic acid having from 1 to 13 carbon atoms and ethylene; and a second copolymer of (i) styrene and butadiene, (ii) styrene, butadiene and acrylonitrile, or (iii) styrene and an acrylic monomer, wherein the first and second copolymers are colloidally dispersed in an aqueous medium comprising a surfactant. The paper coating compositions containing latex dispersion binders of this type preferably exhibit especially desirable coating strength as quantified by the Dry Pick Values which such compositions provide.

This invention relates to new 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives of formula (1) having anticonvulsant activity which are useful as therapeutic agents for the treatment or prevention of epilepsy and other neurological disorders. The invention also concerns processes for preparing these derivatives and novel intermediates used in the preparation of these derivatives.

Disclosed are methods for treating Alzheimer's disease, and other diseases, and / or inhibiting beta-secretase enzyme, and / or inhibiting deposition of A beta peptide in a mammal, by use of compounds of formula (1) wherein the variables R1-R8 and X are defined herein.

Immunomodulators selected from: (a) a saturated or cis-unsaturated C10-C20 fatty alcohol or an ester thereof with a C1-C6 alkanoic acid; (b) a monoester of a C2-C8 alkanediol or of Glycerol with a saturated or cis-unsaturated C10-C20 fatty acid; and (c) a diester of glycerol with a saturated or cis-unsaturated C10-C20 fatty acid, are useful for treatment of inflammation, particularly immunologically-mediated inflammation such as it occurs in autoimmune diseases.

The present invention provides compositions for the treatment of cancer. The compositions include liposomes containing a phosphatidylcholine lipid, a sterol, a PEG-lipid, and a taxane. The PEG-lipid constitutes from about 2 to about 8 mol % of the lipids in the liposome. The taxane is docetaxel esterified at the 2′-O position with a heterocyclyl-(C2-5alkanoic acid). Methods for preparation of liposomal taxanes and treatment of cancer with liposomal taxanes are also disclosed.

The present invention relates to substituted phenyl alkanoic acid compounds designated as the compound of Formula (I) (as described herein) or a tautomer, a stereoisomer, a geometrical isomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, an N-oxide, a S-oxide or a carboxylic acid isostere thereof; which are GPR120 agonists. The present invention also relates to a pharmaceutical composition of compound of Formula (I) for the treatment of diseases or disorder mediated by GPR120.